Drugmakers will not be exempt from cost cuts, says German health minister
Germany’s government has confirmed that pharmaceutical companies will not be exempt from upcoming healthcare cost-cutting measures, despite warnings from major drugmakers about reduced investment in Europe.
Health Minister Nina Warken stated that every sector must contribute to reform efforts aimed at stabilizing the country’s statutory health insurance system. Her comments come as Germany prepares legislation designed to limit rapidly rising healthcare spending.
The planned reforms are part of a broader effort to control costs within Germany’s public health insurance system. While officials acknowledge pressure on the pharmaceutical industry, they insist that exemptions will not be granted and that all sectors must participate in financial adjustments.
Drugmakers have responded with concern, warning that stricter cost controls could make it harder to introduce innovative medicines in Europe. Some companies argue that governments may need to offer higher reimbursement rates if they want continued investment in research and development.
Several major firms have already signaled potential consequences. U.S. pharmaceutical giant Eli Lilly and Company and German-based Boehringer Ingelheim have reportedly reduced planned investments in Germany, citing uncertainty over future policy direction.
Meanwhile, another major player, Pfizer, has indicated that it is reviewing its investment strategy in the country following concerns raised about the new legislative environment.
Despite these tensions, Health Minister Warken emphasized that Germany remains an attractive location for pharmaceutical research and clinical trials. She also noted that Germany currently offers relatively fast access to innovative medicines compared to other European countries, reinforcing the government’s position that the system remains strong even as reforms move forward.